Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: Drug levels and clinical outcomes.
Sign Up to like & getrecommendations! Published in 2021 at "Thrombosis research"
DOI: 10.1016/j.thromres.2021.10.009
Abstract: BACKGROUND Direct oral anticoagulants (DOAC) use remains challenging in obese patients treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and dedicated studies. OBJECTIVE To assess rivaroxaban and apixaban concentrations at different time-points after… read more here.
Keywords: apixaban rivaroxaban; patients treated; treated venous; therapy ranges ... See more keywords